BioNTech Evaluates Rwanda And Senegal For Malaria, Tuberculosis Vaccine Production
After COVID-19, BioNTech Plans To Develop an mRNA Vaccine To Prevent Malaria
Novavax's Malaria Vaccine Candidate Shows 77% Efficacy In Mid-Stage Study
Meridian Bioscience Board Succession Hints At M&A Appetite Change, Canaccord Says